SAT-LB025 Analysis of Benefit/Risk in the Subgroup of Patients with BMI of >=27 Kg/m(2) in the Dapagliflozin DEPICT-1 and -2 Trials in Type 1 Diabetes

Sodium glucose co-transporter-2 inhibitor (SGLT-2i) adjunct therapies have been studied in phase 3 programs for use in people with type 1 diabetes (T1D) and are currently under regulatory review for approval in adults in North America, Europe, and Japan. The DEPICT-1 and -2 programs assessed dapagli...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathieu, Chantal, Dandona, Paresh, Phillip, Moshe, Xu, John, Thorén, Fredrik, Scheerer, Markus, Langkilde, Anna-Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Diabetes Mellitus and Glucose Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552542/
http://dx.doi.org/10.1210/js.2019-SAT-LB025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552542/
http://dx.doi.org/10.1210/js.2019-SAT-LB025

Ejemplares similares